| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; mouse; 1:100; fig s7f
| Taniguchi H, Caeser R, Chavan S, Zhan Y, Chow A, Manoj P, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022;39:110814 pubmed publisher |
- western blot; mouse; loading ...; fig 10p, 10q
| Liu J, Wang C, Cheng T, Rixiati Y, Ji C, Deng M, et al. Circadian Clock Disruption Suppresses PDL1+ Intraepithelial B Cells in Experimental Colitis and Colitis-Associated Colorectal Cancer. Cell Mol Gastroenterol Hepatol. 2021;12:251-276 pubmed publisher |
| Wei C, Huang L, Kreh B, Liu X, Tyutyunyk Massey L, Kawakami M, et al. A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment. Sci Rep. 2023;13:14907 pubmed publisher |
| Rachdi L, Zhou Z, Berthault C, Louren xe7 o C, Fouque A, Domet T, et al. Tryptophan metabolism promotes immune evasion in human pancreatic β cells. EBioMedicine. 2023;95:104740 pubmed publisher |
| Zhang W, Pan X, Xu Y, Guo H, Zheng M, Chen X, et al. Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA. Acta Pharm Sin B. 2023;13:2585-2600 pubmed publisher |
| Shrestha M, Wang D, Ben David Y, Zacksenhaus E. CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer. Oncogenesis. 2023;12:29 pubmed publisher |
| Tseng H, Banerjee S, Qian B, Lai M, Wu T, Hsu T, et al. Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma. Eur J Med Chem. 2023;256:115459 pubmed publisher |
| Xu C, Xia Y, Zhang B, Drokow E, Li H, Xu S, et al. Macrophages facilitate tumor cell PD-L1 expression via an IL-1β-centered loop to attenuate immune checkpoint blockade. MedComm (2020). 2023;4:e242 pubmed publisher |
| Wang S, Kuai Y, Lin S, Li L, Gu Q, Zhang X, et al. NF-κB Activator 1 downregulation in macrophages activates STAT3 to promote adenoma-adenocarcinoma transition and immunosuppression in colorectal cancer. BMC Med. 2023;21:115 pubmed publisher |
| Sato M, Maishi N, Hida Y, Yanagawa Matsuda A, Alam M, Sakakibara Konishi J, et al. Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy. Cancer Med. 2023;12:9760-9773 pubmed publisher |
| De Burghgrave M, Louren xe7 o C, Berthault C, Aiello V, Villalba A, Fouque A, et al. Pancreatic Islet Cells Response to IFNγ Relies on Their Spatial Location within an Islet. Cells. 2022;12: pubmed publisher |
| Shahbandi A, Chiu F, Ungerleider N, Kvadas R, Mheidly Z, Sun M, et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat Cancer. 2022;3:1513-1533 pubmed publisher |
| Mokkapati S, Narayan V, Manyam G, Lim A, Duplisea J, Kokorovic A, et al. Lentiviral interferon: A novel method for gene therapy in bladder cancer. Mol Ther Oncolytics. 2022;26:141-157 pubmed publisher |
| Tengesdal I, Li S, Powers N, May M, Neff C, Joosten L, et al. Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers. Pharmaceuticals (Basel). 2022;15: pubmed publisher |
| Li Y, Wu L, Liu Y, Ma S, Huang B, Feng X, et al. A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells. Transl Oncol. 2022;21:101424 pubmed publisher |
| Barley T, Murphy P, Wang X, Bowman B, Mormol J, Mager C, et al. Mitogen-activated protein kinase phosphatase-1 controls PD-L1 expression by regulating type I interferon during systemic Escherichia coli infection. J Biol Chem. 2022;298:101938 pubmed publisher |
| Pham T, Spaulding C, Shields M, Metropulos A, Shah D, Khalafalla M, et al. Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity. JCI Insight. 2022;7: pubmed publisher |
| Sandker G, Adema G, Molkenboer Kuenen J, Wierstra P, Bussink J, Heskamp S, et al. PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases. Front Immunol. 2022;13:837370 pubmed publisher |
| Shinchi Y, Ishizuka S, Komohara Y, Matsubara E, Mito R, Pan C, et al. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother. 2022;71:2645-2661 pubmed publisher |
| Jin J, Sivakumar I, Mironchik Y, Krishnamachary B, Wildes F, Barnett J, et al. PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model. Cancers (Basel). 2022;14: pubmed publisher |
| Hagemans I, Wierstra P, Steuten K, Molkenboer Kuenen J, van Dalen D, ter Beest M, et al. Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. J Nanobiotechnology. 2022;20:64 pubmed publisher |
| Synn C, Kim S, Lee H, Kim M, Kim J, Lee J, et al. SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. Clin Transl Immunology. 2022;11:e1364 pubmed publisher |
| Ishikura N, Sugimoto M, Yorozu K, Kurasawa M, Kondoh O. Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1low and immune desert‑like mouse tumors. Oncol Rep. 2022;47: pubmed publisher |
| Shi Z, Mori Akiyama Y, Du W, Fultz R, Zhao Y, Ruan W, et al. Loss of H2R Signaling Disrupts Neutrophil Homeostasis and Promotes Inflammation-Associated Colonic Tumorigenesis in Mice. Cell Mol Gastroenterol Hepatol. 2022;13:717-737 pubmed publisher |
| Kim J, Jang H, Lee G, Hur Y, Keum J, Jo J, et al. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. Cells. 2021;11: pubmed publisher |
| Morrissey S, Zhang F, Ding C, Montoya Durango D, Hu X, Yang C, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33:2040-2058.e10 pubmed publisher |
| Lenehan P, Cirella A, Uchida A, Crowley S, Sharova T, Boland G, et al. Type 2 immunity is maintained during cancer-associated adipose tissue wasting. Immunother Adv. 2021;1:ltab011 pubmed publisher |
| El Meskini R, Atkinson D, Kulaga A, Abdelmaksoud A, Gumprecht M, Pate N, et al. Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model. Mol Cancer Res. 2021;19:1422-1436 pubmed publisher |
| Kim S, Kim S, Nam G, Hong Y, Kim G, Choi Y, et al. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. J Immunother Cancer. 2021;9: pubmed publisher |
| Fernandes R, Su L, Nishiga Y, Ren J, Bhuiyan A, Cheng N, et al. Immune receptor inhibition through enforced phosphatase recruitment. Nature. 2020;586:779-784 pubmed publisher |
| Lerbs T, Cui L, King M, Chai T, Muscat C, Chung L, et al. CD47 prevents the elimination of diseased fibroblasts in scleroderma. JCI Insight. 2020;5: pubmed publisher |
| Philippou Y, Sjoberg H, Murphy E, Alyacoubi S, Jones K, Gordon Weeks A, et al. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. Br J Cancer. 2020;123:1089-1100 pubmed publisher |
| Shi Y, Fu Y, Zhang X, Zhao G, Yao Y, Guo Y, et al. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunol Immunother. 2021;70:61-73 pubmed publisher |
| Mondello P, Tadros S, Teater M, Fontan L, Chang A, Jain N, et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10:440-459 pubmed publisher |
| Hong Y, Kim Y, Kim G, Nam G, Kim S, Park Y, et al. Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity. J Extracell Vesicles. 2019;8:1670893 pubmed publisher |
| Schreiber L, Urbiola C, Das K, Spiesschaert B, Kimpel J, Heinemann F, et al. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer. Br J Cancer. 2019;121:647-658 pubmed publisher |
| Burrack A, Spartz E, Raynor J, Wang I, Olson M, Stromnes I. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Cell Rep. 2019;28:2140-2155.e6 pubmed publisher |
| Ritzmann F, Jungnickel C, Vella G, Kamyschnikow A, Herr C, Li D, et al. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer. Sci Rep. 2019;9:10353 pubmed publisher |
| Huang C, Tang X, Li S, Wang Q, Xie B, Xu J, et al. Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell. J Cancer. 2019;10:3472-3480 pubmed publisher |
| Kataru R, Ly C, Shin J, Park H, Baik J, Rehal S, et al. Tumor lymphatic function regulates tumor inflammatory and immunosuppressive microenvironments. Cancer Immunol Res. 2019;: pubmed publisher |
| Jagoda E, Vasalatiy O, Basuli F, Opina A, Williams M, Wong K, et al. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Mol Imaging. 2019;18:1536012119829986 pubmed publisher |
| Yahata T, Mizoguchi M, Kimura A, Orimo T, Toujima S, Kuninaka Y, et al. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci. 2019;110:1279-1292 pubmed publisher |
| Bartee M, Dryja P, Bartee E. Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. J Immunother Cancer. 2019;7:11 pubmed publisher |
| Osum K, Burrack A, Martinov T, Sahli N, Mitchell J, Tucker C, et al. Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes. Sci Rep. 2018;8:8295 pubmed publisher |
| Srinivasan P, Wu X, Basu M, Rossi C, Sandler A. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease. PLoS Med. 2018;15:e1002497 pubmed publisher |
| Dimitrov V, Bouttier M, Boukhaled G, Salehi Tabar R, Avramescu R, Memari B, et al. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. J Biol Chem. 2017;292:20657-20668 pubmed publisher |
| Bartee M, Dunlap K, Bartee E. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res. 2017;77:2952-2963 pubmed publisher |
| Sung S, Ge Y, Dai C, Wang H, Fu S, Sharma R, et al. Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice. J Immunol. 2017;198:2589-2601 pubmed publisher |
| Mascia F, Schloemann D, Cataisson C, McKinnon K, Krymskaya L, Wolcott K, et al. Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas. Int J Cancer. 2016;139:2593-7 pubmed publisher |
| Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher |
